M&A Deal Summary |
|
|---|---|
| Date | 2017-04-18 |
| Target | Nivalis Therapeutics |
| Sector | Life Science |
| Buyer(s) | Alpine Immune Sciences |
| Deal Type | Merger |
| Advisor(s) | Ladenburg Thalmann & Co. (Financial) Latham & Watkins Ballard Spahr (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2007 |
| Sector | Life Science |
| Employees | 142 |
| Revenue | 59M USD (2023) |
Alpine Immune Sciences is focused on developing novel protein-based immunotherapies using its proprietary variant immunoglobulin domain (vIgD™) platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a unique process known as directed evolution, which can produce proteins capable of either enhancing or diminishing an immune response and thereby may apply therapeutically to both oncology and inflammatory diseases. Alpine Immune Sciences was founded in 2007 and is based in Seattle, Washington.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Merger M&A Deals | 1 of 1 |
| State: Colorado M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2017 M&A | 1 of 1 |
